Telo Genomics Announces Agreement for Strategic Advisory Services
Telo Genomics Announces Agreement for Strategic Advisory Services
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has entered into an agreement with Leede Jones Gable Inc. ("Leede") to compensate Leede for strategic advice provided in connection with the Company's recently closed $0.25 non-brokered private placement ("Offering").
安大略省多倫多-(Newsfile Corp.-2023年6月30日)-Telo基因公司(TSXV：TELO)(OTCQB：TDSGF)(“公司“或”Telo“)宣佈已與Leeed Jones Gable Inc.(”李德“)補償李德就本公司最近完成的0.25美元非經紀私募提供的戰略建議(”供奉“)。
Under the agreement, the Company will issue to Leede 150,000 common shares in the capital of the Company, and grant 75,000 common share purchase warrants of the Company (the "Warrants"). Each Warrant will be non-transferable and exercisable to acquire one common share of the Company at a price of $0.40 per common share for a period of 12 months from the date of issuance.
根據該協定，本公司將向李德發行150,000股本公司股本中的普通股，並授予75,000股本公司的普通股認購權證(“認股權證每份認股權證不可轉讓及可行使，以收購本公司一股普通股，價格為每股普通股0.40美元，為期12個月，由發行日期起計。
About Leede Jones Gable Inc.
利德·瓊恩斯·蓋博公司簡介
Leede is a leading independent investment dealer providing a full range of investment products and services to clients across Canada. As an employee-owned firm, Leede Jones Gable Inc. has an entrepreneurial spirit that is built upon a commitment to personal service and professional excellence.
利德是一家領先的獨立投資交易商，為加拿大各地的客戶提供全方位的投資產品和服務。作為一家員工所有的公司，利德·瓊恩斯·蓋博公司擁有一種建立在對個人服務和專業卓越的承諾之上的創業精神。
About Telo Genomics
關於Telo基因組學
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit .
Telo基因組公司是一家生物技術公司，憑藉強大的應用程式和預測解決方案開創了業界最全面的端粒平臺。這些包括腫瘤學和神經系統疾病的液體活組織檢查和相關技術。液體活檢是一個迅速增長的領域，醫學界對此非常感興趣，因為它比傳統的診斷方法侵入性更小，更容易複製。通過將我們團隊在3D端粒定量分析方面的豐富專業知識與分子生物學和人工智慧相結合，以識別與疾病相關的遺傳不穩定性，Telo Genonics正在開發簡單而準確的產品，通過服務於病理學家、臨床醫生、學術研究人員和藥物開發商的需求，改善對患者的日常護理。我們的專利技術的好處已經在150多篇同行評議的出版物和25項臨床研究中得到證實，這些研究涉及3000多名患有多發性癌症和阿爾茨海默病的患者。我們的領先應用程式Telo-MM正在開發中，以向醫療專業人員提供治療多發性骨髓瘤的重要、可操作的資訊，多發性骨髓瘤是一種致命的血癌。欲瞭解更多資訊，請訪問。
For further information, please contact:
如需更多資訊，請聯繫：
Kris Weinberg, CEO
678-429-5582
kris.weinberg@telodx.com
MaRS Centre, South Tower,
101 College Street, Suite 200
Toronto, ON, M5G 1L7
首席執行官克裡斯·溫伯格
678-429-5582
郵箱：kris.weinberg@telodx.com
火星中心，南塔，
學院街101號，套房200
安大略省多倫多，M5G 1L7
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Cautionary Note Regarding Forward-Looking Statements
有關前瞻性陳述的注意事項
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the agreement and the issuance of securities to Leede are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
根據加拿大證券法，本文中包含的某些資訊可能構成“前瞻性資訊”。一般而言，前瞻性資訊可以通過使用前瞻性術語來識別，如“將”，或這些詞語和短語的變體，或某些行動、事件或結果“將”發生的陳述。有關該協定和向Leeed發行證券的前瞻性陳述會受到已知和未知的風險、不確定因素和其他因素的影響，這些風險、不確定性和其他因素可能會導致公司的實際結果、活動水準、業績或成就與這些前瞻性陳述或前瞻性資訊中明示或暗示的內容大不相同，包括資本支出和其他成本。不能保證這些陳述將被證明是準確的，因為實際結果和未來事件可能與這些陳述中預期的大不相同。因此，讀者不應過分依賴前瞻性陳述和前瞻性資訊。除非適用的證券法要求，否則公司不會更新任何通過引用納入本文的前瞻性陳述或前瞻性資訊。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。